Evidence-Based Outcomes for Patients with Advanced Non-Small Cell Lung Cancer

Michael S. Reif; M. Patricia Rivera

doi:10.1055/s-2000-9405

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2000; Volume 21(Number 05): 443-450
DOI: 10.1055/s-2000-9405

Evidence-Based Outcomes for Patients with Advanced Non-Small Cell Lung Cancer

Michael S. Reif, M. Patricia Rivera

Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill North Carolina

Abstract

ABSTRACT

A majority of patients diagnosed with non-small cell lung cancer (NSCLC) will have advanced disease at diagnosis. In the past, systemic therapy (chemotherapy) has demonstrated only slight improvement in survival, hence, practitioners were reluctant to refer patients for cytotoxic therapy. In the past few years, newer chemotherapeutic agents, with increased activity against NSCLC, have been shown to significantly improve median and 1-year survival rates and improve quality of life. Although advanced NSCLC is considered incurable disease, it is, however, potentially treatable disease. This chapter will address the evidence regarding currently available therapies for patients with advanced stage NSCLC.

KEYWORD

Non-small cell lung cancer - advanced stage - chemotherapy

Full Text

References

REFERENCES

1 Perez E A. Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer. Chest . 1998; 114 593-604
2 Cancer Statistics. CA Cancer J Clin . 1999; 49 8-31
3 Cartei G, Cartei F, Cantone A. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst . 1993; 85 794-800
4 Cellerino R, Tummarello D, Guidi F. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol . 1991; 9 1453-1461
5 Cormier Y, Bergeron D, La Forge J. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer . 1982; 50 845-849
6 Ganz P A, Figlin R A, Haskell C M, La Soto N, Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?. Cancer . 1989; 63 1271-1278
7 Helsing M, Bergman B, Thaning L. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised Phase III trial. Joint Lung Cancer Study Group. Eur J Cancer . 1998; 34 1036-1044
8 Kaasa S, Lund E, Thorud E. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer . 1991; 67 2443-2447
9 Quoix E, Dietemann A, Charbonneau J. [Is chemotherapy with cisplatin useful in non small cell bronchial cancer at staging IV?. <~>Results of a randomized study]. Bull du Cancer . 1991; 78 341-346
10 Rapp E, Pater J L, Willan A. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol . 1988; 6 633-641
11 Thongprasert S, Sanguanmitra P, Juthapan W. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: Best supportive care (BSC) versus BSC plus chemotherapy [In Process Citation]. Lung Cancer . 1999; 24 17-24
12 Woods R L, Williams C J, Levi J. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer . 1990; 61 608-611
13 O'Connell J P, Kris M G, Gralla R J. Frquency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol . 1986; 4 1604-1614
14 Albain K S, Crowley J J, LeBlanc M. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol . 1991; 9 1618-1626
15 Ruckdeschel J C, Finkelstein D M, Mason B A. Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V-a randomized comparison of four cisplatin-containing regimens. J Clin Oncol . 1985; 3 72-79
16 Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ . 1995; 311 899-909
17 Marino P, Pampallona S, Preatoni A. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest . 1994; 106 861-865
18 Souquet P J, Chauvin F, Boissel J P. Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer. Lung Cancer . 1995; 12 S147-S154
19 Grilli R, Oxman A D, Julian J A. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough?. J Clin Oncol . 1993; 11 1866-1872
20 Le Chevalier T, Brisgand D, Douillard J Y. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol . 1994; 12 360-367
21 Cardenal F, Lopez-Cabrerizo M P, Anton A. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metaststic non-small-cell lung cancer. J Clin Oncol . 1999; 17 12-18
22 Giaccone G, Postmus P, Debruyne C. Final results of an EORTC phase III study of paclitaxel versus teniposide, in combination with cisplatin, in advanced NSCLC. Proc Am Soc Clin Oncol . 1997; 16(abstract 1653) 460a
23 Belani C P, Natale R B, Lee J S, Socinski M. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung (NSCLC). Proc Am Soc Clin Oncol . 1998; 17(abstract 1751) 455a
24 Bonomi P, Kim K, Chang A. Phase III trial comparing etoposide (E), cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Group (ECOG) trial. Proc Am Soc Clin Onc . 1996; 15(abstr) 382
25 Gatzmeier U, von Pawel J, Gottfried M. Phase III comparative study of high-dose cisplatin (HD-CIS) versus a combination of paclitaxel (TAX) and cisplatin (CIS) in patients with advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol . 1998; 17(abstract 1748) 454a
26 Kelly K, Crowley J, Bunn P A. A Randomized Phase III Trial of Paclitaxel Plus Carboplatin (PC) Versus Vinorelbine Plus Cisplatin (VC) in Untreated Advanced Non-Small Cell Lung Cancer (NSCLC): A Southwest Oncology Group (SWOG) Trial. Proc Am Soc Clin Onc . 1999; (abstract 1777) 18a
27 Sandler A, Nemunaitis J, Dehnam C. Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol . 1998; 17(abstract 1747) 454a
28 Wozniak A J, Crowley J J, Balcerzak S P. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol . 1998; 16 2459-2465
29 Comella P, Frasci G, Panza N. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: A Phase II randomized study of the Southern Italy Cooperative Oncology Group. J Clin Oncol . 1999; 17 1526-1534
30 Comella P, Panz N, Nicolella G. Cisplatin-gemcitabine-vinorelbine vs cisplatin-vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a SICOG phase III trial. Eur J Cancer. 1999; 35(suppl 4)(abstract #977) 247
31 Inoperable non-small-cell lung cancer (NSCLC): A Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer . 1991; 63 265-270
32 Donato V, Zurlo A, Bonfili P. Hypofractionated radiation therapy for inoperable advanced stage non-small cell lung cancer. Tumori . 1999; 85 174-176
33 Curran Jr W. New therapeutic strategies involving radiation therapy for patients with non-small cell lung cancer. Chest . 1995; 302S-305S (302S-305S)
34 Fernandez C, Rosell R, Abad-Esteve A. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol . 1989; 28 29-33
35 Ellis P A, Smith I E, Hardy J R. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer . 1995; 71 366-370
36 Jakkimainen L, Goodwin P J, Pater J. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol . 1990; 8 1301-1309
37 Smith T J, Hillner B E, Neighbors D M. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol . 1995; 13 2166-2173
38 Earle C C, Evans W K. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer. Cancer Prev Control . 1997; 1 282-288
39 Evans W K, Le Chevalier T. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. Eur J Cancer . 1996; 32A 2249-2255